---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-021025"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2023-06-06T23:59:59+00:00"
generated_at: "2026-06-14T06:41:51.080355+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zai Lab partner Novocure's LUNAR Phase 3 trial meets endpoint, shows 3-month OS improvement in metastatic NSCLC

## Summary
- TTFields + standard therapies improved median OS from 9.9 to 13.2 months (HR 0.74, p=0.035) in post-platinum metastatic NSCLC.
- ICI subgroup median OS was 18.5 vs 10.8 months (HR 0.63, p=0.03), an 8-month improvement.
- TTFields was well-tolerated with no added systemic toxicities; only grade 3 device-related AEs.
- Novocure plans PMA submission to FDA in H2 2023; Zai Lab will file MAA to China's NMPA thereafter.
- Zai Lab has exclusive license to develop/commercialize TTFields in Greater China.

## SEC filing metadata
- accession: 0001628280-23-021025
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2023-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828023021025/0001628280-23-021025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828023021025/zlab-20230606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-021025
- JSON: https://secwatch.observer/filing/0001628280-23-021025.json
- Plain text: https://secwatch.observer/filing/0001628280-23-021025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.